<DOC>
	<DOCNO>NCT00324454</DOCNO>
	<brief_summary>Levetiracetam ( Keppra ) use treat partial onset seizure . Its biological effect suggest might also useful treat 3 aspect human motor neuron disease ( MNDs ) effective therapy exists : cramp , spasticity , disease progression .</brief_summary>
	<brief_title>Levetiracetam Cramps , Spasticity Neuroprotection Motor Neuron Disease</brief_title>
	<detailed_description>Cramps MNDs believe occur result high-frequency burst fire alpha motor neuron . Levetiracetam inhibit burst firing epileptic rat hippocampus . Levetiracetam never test cramp human ; however , help another condition believe result burst fire motor nerve : hemi-facial spasm . The mechanisms underlying spasticity MNDs likely involve imbalance excitatory inhibitory influence alpha motor neuron . Levetiracetam may modulate influence number way , include reduce effect zinc beta-carbolines GABA glycine receptor . Levetiracetam reduce phasic ( tonic ) spasticity patient multiple-sclerosis . Levetiracetam may neuroprotective property . In model cerebral ischemia induce occlusion rat internal carotid artery , pre-treatment levetiracetam reduce infarct size dose-dependent manner . In rat inject kainic acid induce calcium overload , oxidative stress neurotoxicity , pretreatment levetiracetam offset kainic acid 's effect . The mechanisms effect may relate levetiracetam 's ability influence calcium current , ability increase release growth factor astrocytes , mechanism would relevant MNDs . Levetiracetam 's ability inhibit histone deacetylase may also help slow MNDs progression . OBJECTIVES : 1 . Assess safety tolerability levetiracetam 9 month patient MNDs . 2 . Determine whether treatment levetiracetam associate reduction cramp , spasticity motor neuron disease progression . METHODS : Open-label , Phase 2 trial 20 adult patient MNDs ( ALS , PLS PMA ) Duke University ALS Clinic . Eligible patient cramps average severity 50/100 point , able provide inform consent , normal renal function stable riluzole dose . Exclusions include pregnancy , unstable mental illness , dementia , drug abuse non-compliance . The first 3 month study baseline period . Over remain 9 month , patient take levetiracetam increase dose 3000mg per day . Outcome measure include adverse event , tolerability , cramp-pain-severity score , cramp-frequency score , modify Ashworth Spasticity Score , Penn Spasm Score , FVC , ALSFRS-R MMT .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Patients MNDs ( ALS , PLS PMA ) cramp average severity 50/100 point , able provide inform consent , normal renal function stable riluzole dose . Pregnancy ; unstable medical illness , dementia ; drug abuse noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>motor neuron disease</keyword>
	<keyword>amyotrophic lateral sclerosis primary lateral</keyword>
	<keyword>sclerosis ; progressive muscular atrophy</keyword>
	<keyword>cramp</keyword>
	<keyword>spasticity</keyword>
</DOC>